Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
24
05
2021
accepted:
12
10
2021
pubmed:
3
12
2021
medline:
8
2
2022
entrez:
2
12
2021
Statut:
ppublish
Résumé
Rectum-preservation for locally advanced rectal cancer has been proposed as an alternative to total mesorectal excision (TME) in patients with major (mCR) or complete clinical response (cCR) after neoadjuvant therapy. The purpose of this study was to report on the short-term outcomes of ReSARCh (Rectal Sparing Approach after preoperative Radio- and/or Chemotherapy) trial, which is a prospective, multicenter, observational trial that investigated the role of transanal local excision (LE) and watch-and-wait (WW) as integrated approaches after neoadjuvant therapy for rectal cancer. Patients with mid-low rectal cancer who achieved mCR or cCR after neoadjuvant therapy and were fit for major surgery were enrolled. Clinical response was evaluated at 8 and 12 weeks after completion of chemoradiotherapy. Treatment approach, incidence, and reasons for subsequent TME were recorded. From 2016 to 2019, 160 patients were enrolled; mCR or cCR at 12 weeks was achieved in 64 and 96 of patients, respectively. Overall, 98 patients were managed with LE and 62 with WW. In the LE group, Clavien-Dindo 3+ complications occurred in three patients. The rate of cCR increased from 8- to 12-week restaging. Thirty-three (94.3%) of 35 patients with cCR had ypT0-1 tumor. At a median 24 months follow-up, a tumor regrowth was found in 15 (24.2%) patients undergoing WW. LE for patients achieving cCR or mCR is safe. A 12-week interval from chemoradiotherapy completion to LE is correlated with an increased cCR rate. The risk of ypT > is reduced when LE is performed after cCR.
Sections du résumé
BACKGROUND
BACKGROUND
Rectum-preservation for locally advanced rectal cancer has been proposed as an alternative to total mesorectal excision (TME) in patients with major (mCR) or complete clinical response (cCR) after neoadjuvant therapy. The purpose of this study was to report on the short-term outcomes of ReSARCh (Rectal Sparing Approach after preoperative Radio- and/or Chemotherapy) trial, which is a prospective, multicenter, observational trial that investigated the role of transanal local excision (LE) and watch-and-wait (WW) as integrated approaches after neoadjuvant therapy for rectal cancer.
METHODS
METHODS
Patients with mid-low rectal cancer who achieved mCR or cCR after neoadjuvant therapy and were fit for major surgery were enrolled. Clinical response was evaluated at 8 and 12 weeks after completion of chemoradiotherapy. Treatment approach, incidence, and reasons for subsequent TME were recorded.
RESULTS
RESULTS
From 2016 to 2019, 160 patients were enrolled; mCR or cCR at 12 weeks was achieved in 64 and 96 of patients, respectively. Overall, 98 patients were managed with LE and 62 with WW. In the LE group, Clavien-Dindo 3+ complications occurred in three patients. The rate of cCR increased from 8- to 12-week restaging. Thirty-three (94.3%) of 35 patients with cCR had ypT0-1 tumor. At a median 24 months follow-up, a tumor regrowth was found in 15 (24.2%) patients undergoing WW.
CONCLUSIONS
CONCLUSIONS
LE for patients achieving cCR or mCR is safe. A 12-week interval from chemoradiotherapy completion to LE is correlated with an increased cCR rate. The risk of ypT > is reduced when LE is performed after cCR.
Identifiants
pubmed: 34855063
doi: 10.1245/s10434-021-11121-8
pii: 10.1245/s10434-021-11121-8
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1880-1889Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Bosset J-F, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006. https://doi.org/10.1056/NEJMoa060829 .
doi: 10.1056/NEJMoa060829
pubmed: 16971718
Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001. https://doi.org/10.1056/NEJMoa010580 .
doi: 10.1056/NEJMoa010580
pubmed: 11547717
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004. https://doi.org/10.1056/NEJMoa040694 .
doi: 10.1056/NEJMoa040694
pubmed: 15496622
Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 2006. https://doi.org/10.1016/j.ejso.2005.09.010 .
doi: 10.1016/j.ejso.2005.09.010
pubmed: 16520017
Beddy D, Hyland JMP, Winter DC, et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2008. https://doi.org/10.1245/s10434-008-0149-y .
doi: 10.1245/s10434-008-0149-y
pubmed: 18846402
Mignanelli ED, Campos-Lobato LF, Stocchi L, et al. Downstaging after chemoradiotherapy for locally advanced rectal cancer: Is there more (tumor) than meets the eye? Dis Colon Rectum. 2010. https://doi.org/10.1007/DCR.0b013e3181bcd3cc .
doi: 10.1007/DCR.0b013e3181bcd3cc
pubmed: 20173481
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010. https://doi.org/10.1016/S1470-2045(10)70172-8 .
doi: 10.1016/S1470-2045(10)70172-8
pubmed: 20692872
Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016. https://doi.org/10.1097/SLA.0000000000000368 .
doi: 10.1097/SLA.0000000000000368
pubmed: 24263329
Luna-Pérez P, Rodríguez-Ramírez S, Vega J, Sandoval E, Labastida S. Morbidity and mortality following abdominoperineal resection for low rectal adenocarcinoma. Rev Investig Clin. 2001;53(5):388–95.
Petrelli NJ, Nagel S, Rodriguez-Bigas M, Piedmonte M, Herrera L. Morbidity and mortality following abdominoperineal resection for rectal adenocarcinoma. Am Surg. 1993;59(7):400–4.
pubmed: 8323072
Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuita R, Guerrieri M. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg. 2012. https://doi.org/10.1002/bjs.8821 .
doi: 10.1002/bjs.8821
pubmed: 22864880
Pucciarelli S, Giandomenico F, De Paoli A, et al. Bowel function and quality of life after local excision or total mesorectal excision following chemoradiotherapy for rectal cancer. Br J Surg. 2016. https://doi.org/10.1002/bjs.10318 .
doi: 10.1002/bjs.10318
pubmed: 27706805
Bujko K, Richter P, Smith FM, et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study. Radiother Oncol. 2013. https://doi.org/10.1016/j.radonc.2012.12.005 .
doi: 10.1016/j.radonc.2012.12.005
pubmed: 23791302
Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum. 2013. https://doi.org/10.1097/DCR.0b013e3182a2303e .
doi: 10.1097/DCR.0b013e3182a2303e
pubmed: 24201388
Rullier E, Rouanet P, Tuech J-J, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017. https://doi.org/10.1016/S0140-6736(17)31056-5 .
doi: 10.1016/S0140-6736(17)31056-5
pubmed: 28601342
Verseveld M, de Graaf EJR, Verhoef C, et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg. 2015. https://doi.org/10.1002/bjs.9809 .
doi: 10.1002/bjs.9809
pubmed: 25847025
Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004. https://doi.org/10.1097/01.sla.0000141194.27992.32 .
doi: 10.1097/01.sla.0000141194.27992.32
pubmed: 15383798
pmcid: 1356472
Habr-Gama A, Santinho B, de Souza PM, Ribeiro U, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998. https://doi.org/10.1007/BF02239429 .
doi: 10.1007/BF02239429
pubmed: 9823808
Habrgama A, Perez R, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006. https://doi.org/10.1016/j.gassur.2006.09.005 .
doi: 10.1016/j.gassur.2006.09.005
Barina A, De Paoli A, Delrio P, et al. Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study. Tech Coloproctol. 2017. https://doi.org/10.1007/s10151-017-1665-1 .
doi: 10.1007/s10151-017-1665-1
pubmed: 28755256
Benson AB, Venook AP, Cederquist L, et al. Colon cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017. https://doi.org/10.6004/jnccn.2017.0036 .
doi: 10.6004/jnccn.2017.0036
Amin MB, Gress DM. AJCC cancer staging manual. 8th edn. New York: Springer; 2017.
doi: 10.1007/978-3-319-40618-3
Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994. https://doi.org/10.1002/1097-0142(19940601)73:11%3c2680::AID-CNCR2820731105%3e3.0.CO;2-C .
doi: 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
pubmed: 8194005
Hope ACA. A simplified Monte Carlo significance test procedure. J R Stat Soc Ser B. 1968. https://doi.org/10.1111/j.2517-6161.1968.tb00759.x .
doi: 10.1111/j.2517-6161.1968.tb00759.x
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2020. Available at: https://www.R-project.org/ . Accessed 11 May 2021.
Jr FEH. rms: Regression modeling strategies. 2020. Available at: https://CRAN.R-project.org/package=rms . Accessed 11 May 2021.
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004. https://doi.org/10.1097/01.sla.0000133083.54934.ae .
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15570203
pmcid: 1356513
Hupkens BJP, Maas M, Martens MH, et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response? Ann Surg Oncol. 2018. https://doi.org/10.1245/s10434-017-6213-8 .
doi: 10.1245/s10434-017-6213-8
pubmed: 30421061
Sloothaak DM, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013. https://doi.org/10.1002/bjs.9112 .
doi: 10.1002/bjs.9112
pubmed: 23536485
D’Alimonte L, Bao QR, Spolverato G, et al. Long-term outcomes of local excision following neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09243-6 .
doi: 10.1245/s10434-020-09243-6
pubmed: 33125570
pmcid: 8043910
Hallam S, Messenger DE, Thomas MG. A systematic review of local excision after neoadjuvant therapy for rectal cancer: Are ypt0 tumors the limit? Dis Colon Rectum. 2016. https://doi.org/10.1097/DCR.0000000000000613 .
doi: 10.1097/DCR.0000000000000613
pubmed: 27602930
Stijns RCH, de Graaf EJR, Punt CJA, et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. JAMA Surg. 2019. https://doi.org/10.1001/jamasurg.2018.3752 .
doi: 10.1001/jamasurg.2018.3752
pubmed: 30304338
Pucciarelli S, Capirci C, Emanuele U, et al. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol. 2005. https://doi.org/10.1245/ASO.2005.03.044 .
doi: 10.1245/ASO.2005.03.044
pubmed: 15827790
Read TE, Andujar JE, Caushaj PF, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum. 2004. https://doi.org/10.1007/s10350-004-0535-x .
doi: 10.1007/s10350-004-0535-x
pubmed: 15108025
Lezoche G, Baldarelli M, Guerrieri M, et al. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc. 2008. https://doi.org/10.1007/s00464-007-9596-y .
doi: 10.1007/s00464-007-9596-y
pubmed: 18553205
Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014. https://doi.org/10.1097/DCR.0b013e3182a84eba .
doi: 10.1097/DCR.0b013e3182a84eba
pubmed: 24807613
Benzoni E, Cerato F, Cojutti A, et al. The predictive value of clinical evaluation of response to neoadjuvant chemoradiation therapy for rectal cancer. Tumori. 2005. https://doi.org/10.1177/030089160509100504 .
doi: 10.1177/030089160509100504
pubmed: 16459636
Zmora O, Dasilva GM, Gurland B, et al. Does rectal wall tumor eradication with preoperative chemoradiation permit a change in the operative strategy? Dis Colon Rectum. 2004. https://doi.org/10.1007/s10350-004-0673-1 .
doi: 10.1007/s10350-004-0673-1
pubmed: 15657651
Maas M, Lambregts DMJ, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015. https://doi.org/10.1245/s10434-015-4687-9 .
doi: 10.1245/s10434-015-4687-9
pubmed: 26198074
pmcid: 4595525
Habr-Gama A, Lynn PB, Jorge JMN, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum. 2016. https://doi.org/10.1097/DCR.0000000000000543 .
doi: 10.1097/DCR.0000000000000543
pubmed: 27602923
Morino M, Allaix ME, Arolfo S, Arezzo A. Previous transanal endoscopic microsurgery for rectal cancer represents a risk factor for an increased abdominoperineal resection rate. Surg Endosc. 2013. https://doi.org/10.1007/s00464-013-2911-x .
doi: 10.1007/s00464-013-2911-x
pubmed: 24170069